Condition: Locally Advanced or Metastatic Breast Cancer · Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd
This study is designed to evaluate the safety and efficacy of SPH4336 combined with letrozole in first-line treatment of locally advanced or metastatic breast cancer
This description comes directly from the study's public registry record.
Shusen Wang · 0086-020-87343811 · wangshs@sysucc.org.cn
Always discuss trial participation with your own doctor first.
| Fujian Cancer Hospital | Fuzhou, Fujian, China | Recruiting |
| Affiliated Cancer Hospital, Sun Yat-sen University | Guangzhou, Guangdong, China | Recruiting |
| The Affiliated Cancer Hospital of Guizhou Medical University | Guiyang, Guizhou, China | Recruiting |
| AnYang Tumor Hospital | Anyang, Henan, China | Recruiting |
| The First Affiliated Hospital of Henan University of Science and Technology | Luoyang, Henan, China | Recruiting |
| Pingxiang People's Hospital | Pingxiang, Jiangxi, China | Recruiting |
| The Second Norman Bethune Hospital of Jilin Univer | Changchun, Jilin, China | Recruiting |
| General Hospital of Ningxia Medical University | Yinchuan, Ningxia, China | Recruiting |
| Peking University Cancer Hospital | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05744687